ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Trastuzumab is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it not given in this study. Nov 2, 2026, 3:40 AM UTC“Trastuzumab rezetecan, a different drug”
  • The role rule had no answer: no treatment entry names it.
  • So Trastuzumab's page does not count this study.
2 links0 made here, not in the record2 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT07624201Trastuzumab Rezetecan andAdebrelimab as NeoadjuvantTherapy for HER2-PositiveMuscle-Invasive BladderCancerHarbin Medical UniversityPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 19 · ClinicalTrials.gov record · Version of 2026-10-19Version of 2026-10-19CONDITIONSUrinary Bladder NeoplasmsNo longer in the registry's filing›As of now · Rule based · Main conditionMain conditionDRUGSTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · Not givenNot given

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Oct 19 · changes seen, not judgments
Nov 2TrastuzumabClaude Opus 5.5Not givenCurrent
As of nowUrinary Bladder NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.